Skip to main content
Clinical Trials/JPRN-UMIN000047107
JPRN-UMIN000047107
Completed
未知

observational study to investigate the safety and efficacy of olaparib combined with bevacizumab therapy after primary chemotherapy plus bevacizumab for Japanese patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. - JGOG3030

Japanese Gynecologic Oncology Group0 sites300 target enrollmentMarch 7, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Ovarian cancer, Fallopian tube cancer, Primary peritoneal cancer
Sponsor
Japanese Gynecologic Oncology Group
Enrollment
300
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 7, 2022
End Date
May 31, 2028
Last Updated
2 years ago
Study Type
Observational
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Patients with active double cancer 2\. Patients judged by the investigator to be inappropriate for participation in this study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
An observational study to evaluate the safety and efficacy of MegaDerm Soft in patients who underwent breast reconstruction using the MegaDerm soft.
KCT0007432Soon Chun Hyang University Hospital Bucheon60
Recruiting
Phase 4
An observational study to evaluate the safety and efficacy of FOLFIRI / FOLFOX plus Cetuximab as first-line therapy inpatients with KRAS wild-type metastatic Colorectal cancerHealth Condition 1: null- Patients with KRAS wild-type metastatic Colorectal cancer
CTRI/2010/091/000161Merck Specialities Pvt Limited5th Floor , Shivsagar EstateDr. Annie Besant RoadMumbai 400018100
Not yet recruiting
Not Applicable
An observational study to evaluate the safety and efficacy of lenvatinib plus pembrolizumab combination therapy for advanced or recurrent uterine cancer after use of platinum-based drugs(GOGO-EM4)
JPRN-UMIN000049997Gynecologic Oncology Group of Osaka(GOGO)100
Recruiting
Phase 4
An Observational Study to evaluate the safety and efficacy of Cetuximab in combination with platinum-based chemotherapy, in the first-line therapy of recurrent/ metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
CTRI/2010/091/000170Merck Specialities Pvt Ltd5th Floor Shiv Sagar Estate, Dr. Aniie Besant Road, WorliMumbai 400018100
Recruiting
Not Applicable
An observational study to investigate the safety and efficacy of niraparib for Japanese patients with recurrent ovarian cancer: maintenance therapy for platinum-sensitive recurrent treatment and monotherapy for late-line treatmentOvarian cancer, fallopian tube cancer, primary peritoneal cancer
JPRN-UMIN000046970Japanese Gynecologic Oncology Group180